Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor

doi:10.3748/wjg.15.5091

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 40

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2921)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

358

HTML

2242

Figures (1-2)

147

Tables (1-2)

174

Sum=2921

Oct 28, 2009 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 28, 2009; 15(40): 5091-5096
Published online Oct 28, 2009. doi: 10.3748/wjg.15.5091

Open in New Tab Full Size Figure Download Figure

Figure 1 Gross appearance of the opened stomachs in the experimental groups. A: Appearance of normal mucosa of the stomach (Saline); B: Severe mucosal injury (Indomethacin); C: Diminished mucosal injury (Group F5); D: Gastric mucosa without any lesion (Group F20); E: Partially protected gastric mucosa against the harmful effect of indomethacin (Group V2); F: Lesion free gastric mucosa (Group V10).

Open in New Tab Full Size Figure Download Figure

Figure 2 Normal rat gastric mucosa in the saline group and Group V10 (A and C, HE; × 100); gastric mucosal hemorrhage and necrosis in indomethacin group and Group V2 (B and D, HE; × 200, × 100) are shown.

Citation: Karakaya K, Hanci V, Bektas S, Can M, Ucan HB, Emre AU, Tascılar O, Turan IO, Comert M, Irkorucu O, Cakmak GK. Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor. World J Gastroenterol 2009; 15(40): 5091-5096
URL: https://www.wjgnet.com/1007-9327/full/v15/i40/5091.htm
DOI: https://dx.doi.org/10.3748/wjg.15.5091